Journal article
Interleukin 13-mediated colitis in the absence of IL-4Rα signalling.
- Abstract:
- Sufficient evidence points to interleukin 13 (IL-13) as an important pathological factor in UC and raises hopes to a promising new treatment strategy.1–3 However, the outcomes of two recent clinical trials, both published in Gut 2015, suggest otherwise.4 ,5 A commentary published in the same issue described these results as crushing the enthusiasm for anti-IL-13 treatment in UC.6 In this letter, we show evidence that the disease outcome is determined by the type of signalling pathway used by IL-13 in mice. Therefore, we suggest that directly blocking IL-13 remains a potential treatment strategy for a subset of patients with UC that have elevated tissue IL-13 production.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 3.8MB, Terms of use)
-
- Publisher copy:
- 10.1136/gutjnl-2016-313208
Authors
- Publisher:
- BMJ Publishing Group
- Journal:
- Gut More from this journal
- Publication date:
- 2017-02-01
- Acceptance date:
- 2017-02-05
- DOI:
- ISSN:
-
0017-5749 and 1468-3288
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:683980
- UUID:
-
uuid:ed81cd46-8a0d-4691-8917-863139212e79
- Local pid:
-
pubs:683980
- Source identifiers:
-
683980
- Deposit date:
-
2017-05-05
Terms of use
- Copyright holder:
- BMJ Publishing Group Ltd and British Society of Gastroenterology
- Copyright date:
- 2017
- Notes:
- © 2017 BMJ Publishing Group Ltd and British Society of Gastroenterology. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
If you are the owner of this record, you can report an update to it here: Report update to this record